Enhanced Positron Imaging Tomography Imaging Agent Compositions and Methods for Bacterial Infection Diagnosis and Treatment

The present inventive concept relates to novel positron imaging tomography (PET) imaging agent compositions and methods that enhance the accuracy and efficiency of bacterial infection diagnosis and treatment. These compositions and methods utilize a dynamically adjustable ratio of 4-amino-2-[18F]-fluorobenzoic acid to 4-amino-2-[19F]-fluorobenzoic acid, allowing for real-time optimization of treatment efficacy and reduced radiation exposure to patients.

The original patent disclosed a PET imaging agent composition for bacterial infection diagnosis, but it had limitations in terms of treatment efficacy and radiation exposure. The present inventive concept addresses these limitations by introducing a novel bacterial infection detection module, dynamically adjustable ratio of 4-amino-2-[18F]-fluorobenzoic acid to 4-amino-2-[19F]-fluorobenzoic acid, and real-time optimization of treatment efficacy, thereby providing a more efficient and safer diagnosis and treatment approach.

The inventive concept comprises a novel PET imaging agent composition consisting of the compound having the structure:, or a salt of the compound; 4-amino-2-[19F]-fluorobenzoic acid or a salt of 4-amino-2-[19F]-fluorobenzoic acid; and at least one acceptable carrier. The composition is formulated to reduce radiation exposure to patients by at least 20%. The inventive concept also includes a system for monitoring bacterial infection treatment efficacy, which provides real-time feedback on treatment progress. Furthermore, the inventive concept encompasses a method for optimizing the ratio of 4-amino-2-[18F]-fluorobenzoic acid to 4-amino-2-[19F]-fluorobenzoic acid, comprising the steps of determining the bacterial infection type, selecting a predetermined ratio range based on the infection type, and adjusting the ratio within the selected range to optimize treatment efficacy.

The present inventive concept is novel and non-obvious in that it introduces a dynamically adjustable ratio of 4-amino-2-[18F]-fluorobenzoic acid to 4-amino-2-[19F]-fluorobenzoic acid, which allows for real-time optimization of treatment efficacy and reduced radiation exposure to patients. This is a significant improvement over the original patent, which did not provide for such dynamic adjustment.

Alternative embodiments of the inventive concept may include the use of different carrier materials, varying the ratio of 4-amino-2-[18F]-fluorobenzoic acid to 4-amino-2-[19F]-fluorobenzoic acid, or incorporating additional components to enhance treatment efficacy. Variations of the inventive concept may also include the development of new PET imaging agent compositions for specific types of bacterial infections.

The present inventive concept has significant commercial potential in the medical imaging and pharmaceutical industries, particularly in the area of bacterial infection diagnosis and treatment. The target market includes hospitals, clinics, and research institutions, as well as pharmaceutical companies developing new treatments for bacterial infections.